Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
47
datasets available to search
ShareScore release 0.9.0
Dataset results
47 results for “junction line”
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
ClinicalTrials.gov study NCT01585987. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecula
ClinicalTrials.gov study NCT02589496. IPD Sharing: YES. Countries: 1. Publications: 0.
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
ClinicalTrials.gov study NCT03777657. IPD Sharing: YES. Countries: 13. Publications: 5.
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
ClinicalTrials.gov study NCT01142388. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov study NCT02545504. IPD Sharing: NO. Countries: 16. Publications: 1.
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy W
ClinicalTrials.gov study NCT03019588. IPD Sharing: YES. Countries: 4. Publications: 1.
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-
ClinicalTrials.gov study NCT03933449. IPD Sharing: YES. Countries: 1. Publications: 1.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
ClinicalTrials.gov study NCT06346392. IPD Sharing: YES. Countries: 19. Publications: 1.
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
ClinicalTrials.gov study NCT02934464. IPD Sharing: NO. Countries: 1. Publications: 2.
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction C
ClinicalTrials.gov study NCT01123473. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (M
ClinicalTrials.gov study NCT02564263. IPD Sharing: YES. Countries: 0. Publications: 2.
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
ClinicalTrials.gov study NCT02628951. IPD Sharing: Not stated. Countries: 1. Publications: 1.
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
ClinicalTrials.gov study NCT01697072. IPD Sharing: Not stated. Countries: 27. Publications: 2.
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
ClinicalTrials.gov study NCT02494583. IPD Sharing: YES. Countries: 0. Publications: 6.
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
ClinicalTrials.gov study NCT04281576. IPD Sharing: UNDECIDED. Countries: 1. Publications: 8.
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
ClinicalTrials.gov study NCT03959293. IPD Sharing: NO. Countries: 1. Publications: 2.
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
ClinicalTrials.gov study NCT03469557. IPD Sharing: YES. Countries: 1. Publications: 1.
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
ClinicalTrials.gov study NCT00891878. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
ClinicalTrials.gov study NCT06731478. IPD Sharing: YES. Countries: 26. Publications: 0.
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov study NCT06841679. IPD Sharing: NO. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.